Evaluation of the immunogenicity and safety of GlaxoSmithKline Biolgical's HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects.

Trial Profile

Evaluation of the immunogenicity and safety of GlaxoSmithKline Biolgical's HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Apr 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 24 Aug 2007 Status changed from recruiting to in progress.
    • 10 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top